An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome

Fragile X Syndrome Clinical Trial

Official title:

An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05367960
• Other study ID #: BPN14770-CNS-302
• Status: Enrolling by invitation
• Phase: Phase 3
• Start date: November 1, 2022
• Est. completion date: December 2025

Study information

• Verified date: January 2024
• Source: Tetra Discovery Partners
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a 2-year, open-label extension (OLE) study for subjects completing one of two double-blind clinical trials with BPN14770, Study BPN14770-CNS-301(in adult males) and Study BPN14770-CNS-204 (in adolescent males).

Description:

This is a two-year open-label extension (OLE) study for subjects completing one of two double-blind clinical trials with BPN14770, Study BPN14770-CNS-301(in adult males) and Study BPN14770-CNS-204 (in adolescent males). The primary objective of this OLE is to assess the long-term safety and tolerability of BPN14770 in these subjects with fragile X syndrome (FXS) who were treated in one of those parent clinical trials.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 300
• Est. completion date: December 2025
• Est. primary completion date: February 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 9 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Subject has completed the Week 13 visit, whether on treatment or discontinued from treatment, from one of two parent clinical trials with

BPN14770:

1. Study 204

2. Study 301 Subjects who discontinued study treatment early due to AEs deemed related to study treatment by the investigator in one of the parent studies will NOT be eligible, regardless of whether the Week 13 visit was completed.

2. Subjects with a history of seizure disorder who are currently receiving treatment with antiepileptics must have remained seizure-free during the parent study. Any subject experiencing a seizure during the parent study is not eligible to continue into this long-term safety study.

3. Subject must be willing to practice barrier methods of contraception while on study, if sexually active. Abstinence is also considered a reasonable form of birth control in this study population.

4. Subject has a parent, legal authorized guardian, or consistent caregiver.

5. Subject and caregiver are able to attend the clinic regularly and reliably.

6. If subject is his own legal guardian, he is able to understand and sign an informed consent form to participate in the study.

7. For subjects who are not their own legal guardian, subject's parent/legally authorized guardian is able to understand and sign an informed consent form for their child to participate in the study.

8. If subject is not his own legal guardian, subject must provide assent for participation in the study if he has the cognitive ability to do so.

Exclusion Criteria:

• 1. History of, or current cardiovascular, renal, hepatic, respiratory, gastrointestinal, psychiatric, neurologic, cerebrovascular, or other systemic disease that would place the subject at risk or potentially interfere with the interpretation of the safety, tolerability, or efficacy of the study treatment. Common conditions such as mild hypertension, etc. are allowed per the principal investigator's (PI) judgement as long as they are stable and controlled by medical therapy that is constant for at least 4 weeks before randomization.

2. Renal impairment, defined as serum creatinine >1.25×ULN per the latest available laboratory results from the parent study.

3. Cirrhosis, unstable chronic liver disease or acute liver disease. Hepatic impairment, defined as ALT or AST elevation > 2 × ULN per the latest available laboratory results from the parent study. Subjects with stable chronic hepatitis B on oral anti-viral therapy and subjects cured of chronic hepatitis C are allowed. Subjects with Gilbert syndrome are allowed.

4. Clinically significant abnormalities, in the investigator's judgement, in safety laboratory tests, vital signs, or ECG, as measured at the final visit of the parent study.

5. Substance abuse documented during the parent study.

6. Significant hearing or visual impairment that may affect the subject's ability to complete the test procedures.

7. Concurrent major psychiatric condition (eg, major depressive disorder, schizophrenia, or bipolar disorder) as confirmed by the investigator. Subjects with additional diagnosis of autism spectrum disorder or anxiety disorder will be allowed.

8. Subject has active diseases that would interfere with participation, such as acquired immunodeficiency disorder, hepatitis C, hepatitis B, or tuberculosis.

9. Subject has participated in another clinical trial within the 30 days preceding screening OTHER THAN one of the two studies required per Inclusion Criteria 1.

Related Conditions & MeSH terms

• Fragile X Syndrome
• Syndrome

Intervention

Drug:
• Zatolmilast/ BPN14770
25mg zatolmilast/BPN14770 (Adults) or 15 mg zatolmilast/BPN14770 (Adolescents <43 kg)

Locations

Country	Name	City	State
United States	Emory University School of Medicine	Atlanta	Georgia
United States	Kennedy Krieger Institute	Baltimore	Maryland
United States	Rush University Medical Center	Chicago	Illinois
United States	Cincinatti Children's Hospital Medical Center	Cincinnati	Ohio
United States	Children's Hospital Colorado	Denver	Colorado
United States	Greenwood Genetic Center	Greenville	South Carolina
United States	Amnova Clinical Research	Irvine	California
United States	University of Kansas Medical Center	Kansas City	Kansas
United States	Suburban Research Associates	Media	Pennsylvania
United States	Icahn School of Medicine at Mount Sinai	New York	New York
United States	CHOC Thompson Autism Center	Orange	California
United States	MIND Institute UC Davis Medical Center	Sacramento	California
United States	University of Utah and Primary Childrens Hospital	Salt Lake City	Utah
United States	Clinic for Special Children	Strasburg	Pennsylvania
United States	U Mass	Worcester	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Tetra Discovery Partners

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability of BPN14770	Long-term safety and tolerability of BPN14770 in these subjects with fragile X syndrome (FXS) who were treated in one of those parent clinical trials. Safety/tolerability endpoint: Treatment Emergent Adverse Events (TEAEs), which will be coded using the Medical Dictionary for Regulatory Activities. Subject incidence of each system organ class and unique preferred term will be tabulated, including all TEAEs, at least possibly related TEAEs, TEAEs resulting discontinuation of study treatment,TEAEs by intensity, and treatment-emergent SAEs. The safety analysis will be descriptive in nature.	24 months
Secondary	National Institute of Health (NIH)- Toolbox Cognitive Battery (TCB)	National Institute of Health (NIH)- Toolbox Cognitive Battery (TCB): cognitive battery assessing cognition from baseline to week 6, 12, 24, 26, 52 in the NIH-TCB CCC, which is calculated from the Picture Vocabulary and Oral Reading domains.	24 Months
Secondary	Numerical rating scale scores (NRS) scores	Numerical rating scale scores (NRS) scores: parent(s), legal authorized guardian(s), or consistent caregiver(s)-rated assessment of subject-specific behavioral anchors for domains of Daily Function, Language, Academic Skills (subjects from Study 204 only), and Emotions/Behaviors versus Baseline The 3 subject-specific behaviors per domain, as selected by the caregiver in the parent study, will be used for rating throughout the clinical trial. For each of the 3 behaviors chosen within each domain, the parent(s), legal authorized guardian(s), or consistent caregiver(s) will rate the individual from 0 "worst problem" to 10 "no problem at all" so that improvements or worsening in the specific behavior over the treatment period can be evaluated. The caregiver completing the assessment should remain the same at all applicable visits throughout the trial.	24 Months
Secondary	Caregiver Global Impression of Improvement (CaGI-I) assessments:	Caregiver Global Impression of Improvement (CaGI-I) assessments: for the general domains of Daily Function, Language, Academic Skills (subjects from Study 204 only), and Emotions/Behaviors versus baseline. The CaGI-I is a global measure to provide a caregiver's perspective of a subject's overall condition. The assessment of improvement is a 7-point scale that requires the caregiver to assess how much the subject's illness has improved or worsened relative to a baseline state (Week 13 of the parent study) at the beginning of the intervention, and rated as: 1, very much better; 2, much better; 3, a little better; 4, no change; 5, a little worse; 6, much worse; or 7, very much worse.	24 Months
Secondary	Clinical Global Impression Severity (CGI-S) assessments:	Clinical Global Impression Severity (CGI-S) assessments: for general domains of Daily Function, Language, Academic Skills (subjects from Study 204 only), and Emotions/Behaviors versus baseline. In this study, the general domains of Daily Function, Language, Academic Skills (Study 204 subjects only), and Emotions/Behaviors will be assessed using the CGI-S and CGI-I assessment tools. The assessment of severity will be made with a 7-point scale: 1, none; 2, very mild; 3, mild; 4, moderate; 5, marked; 6, severe; 7, extremely severe. The comparison will be made with respect to the overall experience of the clinician with individuals of the same age and sex. In this study, the general domains of Daily Function, Language, Academic Skills (Study 204 subjects only), and Emotions/Behaviors will be assessed. The CGI-S must be administered by the same rater for a given subject at all applicable visits throughout the trial.	24 Months
Secondary	Vineland-3 Adaptive Behavior Scale (Vineland-3)	Vineland-3 Adaptive Behavior Scale (Vineland-3): clinician-administered comprehensive interview yielding adaptive behavior composite score and domain standard scores in domains of communication (receptive, expressive, and written adaptive language functions), daily living skills (personal, domestic, and community skills), and socialization (interpersonal relationships, play and leisure time, and coping abilities) versus baseline. The Vineland-3 is a clinician-administered comprehensive interview yielding adaptive behavior composite score and domain standard scores in domains of: Communication (receptive, expressive, and written adaptive language functions); Daily Living Skills (personal, domestic, and community skills); and Socialization (interpersonal relationships, play and leisure time, and coping abilities) (Pepperdine 2017).	24 Months
Secondary	Verbal Knowledge Test from the Stanford-Binet (ed 5) IQ assessment	Verbal Knowledge Test from the Stanford-Binet (ed 5) IQ assessment versus baseline.; The Verbal Knowledge test is a specific subtest within the SB-5 instrument. This test asks an individual to define everyday words. A full SB-5 assessment of IQ obtained anytime in the 6 months before Day 1 may have been used, provided that individual items scores or z-deviation scores for each item were available. If the required assessment was not available in this time frame, the full SB-5 assessment was completed within the screening window and prior to conducting the NIH-TCB assessments at screening. The same screening SB-5 used in the parent study should be used for the screening assessment in this OLE study. The SB-5 subtest for Verbal Knowledge test does not need be performed at screening, since the results from the parent study is available; the Verbal Knowledge test must be performed at Week 52/early termination.	24 Months
Secondary	Aberrant Behavior Checklist (ABC) scores	Aberrant Behavior Checklist (ABC) scores: parent(s), legal authorized guardian(s), or consistent caregiver(s)-rated scale with six subscales to assess irritability, lethargy, hyperactivity, inappropriate speech, and social avoidance, using the FXS-specific factoring system (ABC-FX) versus baseline. The ABC is a 58-item parent(s), legal authorized guardian(s), or consistent caregiver(s) rating scale used to assess behaviors in FXS across 6 dimensions or subscales: inappropriate speech, irritability, hyperactivity, lethargy/withdrawal, stereotypy, and social avoidance (Sansone 2012).; Items are evaluated on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). This scale has been used extensively in FXS in clinical trials and other projects. The ABC will be scored using the FXS-specific factoring system (ABC-FX). The caregiver completing the assessment should remain the same at all applicable visits throughout the trial.	24 Months
Secondary	Anxiety, Depression, and Mood Scale (ADAMS) scores	Anxiety, Depression, and Mood Scale (ADAMS) scores: parent(s), legal authorized guardian(s), or consistent caregiver(s)-rated scale with a total score and six subscores to assess inappropriate speech, irritability, hyperactivity, lethargy/withdrawal, stereotypy, and social avoidance versus baseline. The ADAMS is a 28-item behavior-based informant instrument rated by the parent(s), legal authorized guardian(s), or consistent caregiver(s). The scale is composed of 5 factors, which address Manic/Hyperactive Behavior, Depressed Mood, Social Avoidance, General Anxiety, and Obsessive/Compulsive Behavior. A caregiver identified upon enrollment of subject should have intimate knowledge of the subject's situation and level of impairment to be able to provide accurate information as required to complete the ADAMS. The caregiver completing the assessment should remain the same at all applicable visits throughout the trial.	24 Months